Xencor, Inc Lessee, Operating Lease, Liability, to be Paid, after Year Five
Xencor, Inc (XNCR) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $48.44 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-02-25
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $48.44M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $57.10M.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $57.10M.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $57.10M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $48.44M 10-K · filed 2026-02-25 |
| 2024-12-31 | $57.10M 10-K · filed 2025-02-27 |
| 2024-09-30 | $57.10M 10-Q/A · filed 2025-02-24 |
| 2024-06-30 | $57.10M 10-Q/A · filed 2025-02-24 |
| 2024-03-31 | $57.10M 10-Q/A · filed 2025-02-24 |
| 2023-12-31 | $66.44M 10-K/A · filed 2025-02-24 |
| 2023-09-30 | $66.44M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $66.44M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $66.44M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $75.51M 10-K · filed 2023-02-27 |
| 2022-09-30 | $49.41M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $46.69M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $46.69M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $52.12M 10-K · filed 2022-02-24 |
| 2021-09-30 | $52.12M 10-Q · filed 2021-11-08 |
| 2021-03-31 | $3.86M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $5.34M 10-K · filed 2021-02-24 |
| 2020-09-30 | $1.24M 10-Q · filed 2020-11-06 |
| 2019-12-31 | $2.28M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |